Dr. Jekkie Kim advises life sciences and technology companies, as well as their investors and lenders on a broad range of matters. She focuses her practice on strategic licensing and collaborations, including university spin-outs and collaborations with pharmaceutical companies; royalty and revenue monetizations; cross border joint ventures, with a focus on out-bound greater China transactions; carve out asset sale transactions; complex commercial transactions, including research and development collaboration agreements, manufacturing and supply agreements and distribution agreements; digital health and artificial intelligence matters; and transactional support for capital markets deals, M&A transactions, emerging company and venture capital matters, debt financings and other matters. 

With her background as a medical doctor with clinical experience and her role as a member of the Institutional Review Board at Massachusetts General Hospital, Dr. Kim has developed a unique perspective in guiding clients through a wide spectrum of complex transactional issues. She proposes creative, efficient and effective strategies, enabling her to quickly understand the ins and outs of her clients' businesses and advise on a wide range of issues based on client needs.

Dr. Kim regularly speaks and writes on healthcare, life sciences, and digital health related topics. She is an advisor to SPARK NS, an independent nonprofit translational research organization dedicated to efficiently advancing promising neuroscience discoveries from the lab to the clinic, and SPARK Program at the Stanford University that allows Stanford students and professors to generate drug and diagnostic proofs-of-concept for potential commercialization, using academic approaches combined with industry standards.

Prior to joining the firm, Dr. Kim was a partner at another international law firm.